Aim: to compare the effectiveness of standard antimicrobial monochemotherapy and two modes of combined pharmacotherapy with the additional administration of various antioxidants in patients with chronic bacterial prostatitis (CBP).
Material and methods. 90 patients with CBP aged 24-46 years (mean age 38.2±1.4 years) were examined (main group) and 30 clinically healthy men aged 20-45 years (average age 35.5±1.5 years) (control group). All men before and after treatment were surveyed using the CPSI–QL questionnaire, standard bacteriological and cytological studies, and parameters of the oxidative status of prostatic secretion (the amount and activity of reactive oxygen species (ROS), the level of diene conjugates, malondialdehyde, zinc, superoxide dismutase (SOD) activity) were studied. The studies were conducted in 3 groups of patients. Group 1 (n=15) received levofloxacin 500 mg / day orally for 28 days. Group 2
(n=15) received levofloxacin 500 mg /day orally in combination with zinc picolinate 22 mg / day orally for 28 days. Group 3 (n=15) received levofloxacin 500 mg /day orally in combination with L–carnitine tartrate 1000 mg / day orally for 28 days.
Results and discussion. Group 1 demonstrated the worst results in terms of microbiological efficacy, dynamics of normalization of clinical and laboratory parameters, oxidative status of the prostate gland and tolerability of treatment. According to all these characteristics, the results of pharmacotherapy in groups 2 and 3 were significantly better than group 1 (p<0.05) with an unreliable difference between the results (p<0.1).
Conclusion. Additional personalized administration of antioxidants (zinc or L-carnitine) to etiotropic antimicrobial chemotherapy significantly improves clinical and laboratory results of CBP pharmacotherapy, while reducing the frequency of side effects.

Keywords: combined pharmacotherapy, antimicrobial chemotherapy, chronic bacterial prostatitis (CBP), antioxidant, L-carnitine, zinc, antioxidants, side effects